Alzheimer’s disease (AD), the most prevalent form of dementia, remains incurable mainly due to our failings in the search for effective pharmacological strategies. Here, we describe the development of targeted multimodal polypeptide-based nanoconjugates as potential AD treatments. Treatment with polypeptide nanoconjugates bearing propargylamine moieties and bisdemethoxycurcumin or genistein afforded neuroprotection and displayed neurotrophic effects, as evidenced by an increase in dendritic density of pyramidal neurons in organotypic hippocampal culture. The additional conjugation of the Angiopep-2 targeting moiety enhanced nanoconjugate passage through the blood-brain barrier and modulated brain distribution with nanoconjugate accumulation in neurogenic areas, including the olfactory bulb. Nanoconjugate treatment effectively reduced neurotoxic β amyloid aggregate levels and rescued impairments to olfactory memory and object recognition in APP/PS1 transgenic AD model mice. Overall, this study provides a description of a targeted multimodal polyglutamate-based nanoconjugate with neuroprotective and neurotrophic potential for AD treatment.

Un estudio liderado por María Jesús Vicent, jefa del Laboratorio de Polímeros Terapéuticos del CIPF de València ha validado con éxito en animales un tratamiento para la enfermedad de alzhéimer basado en la nanomedicina, en el que se ha demostrado que los nanofármacos basados en polipéptidos dirigidos atraviesan eficazmente la barrera hematoencefálica (BHE).

https://cadenaser.com/emisora/2021/04/15/radio_valencia/1618474443_470234.html

https://amp.europapress.es/comunitat-valenciana/noticia-investigadores-prueban-exito-animales-tratamiento-alzheimer-basado-nanomedicina-20210415123325.html?__twitter_impression=true

https://advances.sciencemag.org/content/7/13/eabf9180

Leave a Reply

Your email address will not be published. Required fields are marked *